26.79
0.02 (0.07%)
| 前收盘价格 | 26.77 |
| 收盘价格 | 26.78 |
| 成交量 | 1,543,306 |
| 平均成交量 (3个月) | 3,168,638 |
| 市值 | 1,426,323,456 |
| 预期市盈率 (P/E Forward) | 25.45 |
| 价格/销量 (P/S) | 974.52 |
| 股市价格/股市净资产 (P/B) | 49.03 |
| 52周波幅 | |
| 利润日期 | 13 Aug 2026 |
| 稀释每股收益 (EPS TTM) | -3.69 |
| 总债务/股东权益 (D/E MRQ) | 3.98% |
| 流动比率 (MRQ) | 10.44 |
| 营业现金流 (OCF TTM) | -127.65 M |
| 杠杆自由现金流 (LFCF TTM) | -72.82 M |
| 资产报酬率 (ROA TTM) | -58.15% |
| 股东权益报酬率 (ROE TTM) | -150.50% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | KalVista Pharmaceuticals, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | -4.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.00 |
|
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 1.47% |
| 机构持股比例 | 112.39% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合